In a middle cerebral artery occlusion model of stroke, the administration of the MAGL inhibitor JZL184 (Figure 2), alone or in combination with the tissue plasminogen activator, determined the reduction of brain edema and infarct volume, reducing neuronal loss, in a CB1R-dependent manner [86]. Here, MGLL is linked to stroke disorder.